Summary
Biogenix Pharma Sustanon 250 was analyzed to verify its composition and potency. The sample was submitted by the manufacturer, Biogenix Pharma, and tested by an independent analytical laboratory. The analysis aimed to determine whether the testosterone blend contained the expected concentration of its active ingredients: Testosterone Propionate, Testosterone Phenylpropionate, Testosterone Isocaproate, and Testosterone Decanoate.
The testing revealed a significant underdosing of all four testosterone esters compared to the label claim. The results indicate that the product contained only 12–18% of the expected testosterone ester concentrations, representing a major deviation from the labeled specifications.
Detailed Report
Product Overview
- Manufacturer: BiogenixPharma
- Product Name: Sustanon 250
- Active Ingredients: Testosterone Propionate, Testosterone Phenylpropionate, Testosterone Isocaproate, Testosterone Decanoate
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #40987
- Testing Ordered: 2 April 2024
- Sample Received: 12 April 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Biogenix Pharma (Manufacturer)
- Analysis Paid For By: Biogenix Pharma (Manufacturer)
Testing Results
| Compound | Measured Concentration (mg) | Expected Concentration (mg) | Accuracy (%) | Variance (%) |
|---|---|---|---|---|
| Testosterone Propionate | 3.95 | 30.00 | 13.17 | -86.83 |
| Testosterone Phenylpropionate | 8.76 | 60.00 | 14.60 | -85.40 |
| Testosterone Isocaproate | 10.75 | 60.00 | 17.92 | -82.08 |
| Testosterone Decanoate | 12.23 | 100.00 | 12.23 | -87.77 |
These findings indicate severe underdosing across all tested testosterone esters.
Verification Details
- Verification URL: https://janoshik.com/tests/40987_LPY5AR7ZQ1NQ
Evaluation of Manufacturer-Submitted Testing
This report was funded and submitted by Biogenix Pharma, the product’s manufacturer. Manufacturer-funded testing may introduce potential biases, including selective sample submission, where only the best-quality batches are provided for analysis. While independent laboratory testing provides transparency, these results strongly suggest that this batch of Biogenix Pharma Sustanon 250 does not meet label claims.
Given the severe underdosing observed, users should exercise caution and consider verifying additional independent testing before relying on this product for expected results. Comparing these findings with independent third-party analyses is strongly encouraged.
Conclusion
The lab analysis of Biogenix Pharma Sustanon 250 revealed that all four testosterone esters were significantly underdosed, containing only 12–18% of the stated label claim. Despite being submitted by the manufacturer, the findings strongly indicate that this batch does not meet the expected pharmaceutical standards.
This report serves an educational and harm reduction purpose, providing transparency regarding product quality and consistency. Consumers should remain critical of manufacturer-funded testing and seek independent third-party verification whenever possible.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, these results demonstrate significant deviations from the label claim. Readers are encouraged to interpret this information critically and compare findings with third-party independent lab testing.
